|Slideshows|June 19, 2020

Dispelling New Myths about Masks (and Shoes)

It’s a good idea to wear a mask while exercising and to thoroughly clean shoes to avoid bringing COVID-19 into the home, correct? Here are a few new myths your patients may be sharing.

The World Health Organization's COVID-19 Mythbusters page has been updated again and several of the newest misconceptions reflect the global shift toward less restrictive lifestyles. Surgical or cloth masks have their place in the effort to stem virus spread and you may need to help educate your primary care patients on when--and when not--to use them. The following slides highlight new fictions posted the the WHO page and recap several stubborn ones.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related to this article

October 26th, 2026

Elinzanetant Reduced Menopausal VMS Frequency by ≥50% in 67% of Women at Week 12: TMS 2026

TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.

October 26th, 2026

Nearly 80% of Women May Not Initiate Menopause Hormone Therapy: A Q&A With Intira Sriprasert, MD, PhD

TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.

October 23rd, 2026

Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

October 23rd, 2026

JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.

October 23rd, 2026

More Frequent Physical Activity Linked to Fewer Perimenopause Symptoms in Global Study

TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.

October 22nd, 2026

Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study

TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.

October 21st, 2026

Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women

TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.

October 20th, 2026

Insulin Resistance May Partly Explain Higher Cardiovascular Risk After Premature Menopause

TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.

Dispelling New Myths about Masks (and Shoes)

Related to this article

Trending on Patient Care Online

3 Questions Primary Care Physicians Should Ask About Menopause Symptoms, With Stephanie Faubion, MD

Elinzanetant Reduced Menopausal VMS Frequency by ≥50% in 67% of Women at Week 12: TMS 2026

Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS

Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study

Nearly 80% of Women May Not Initiate Menopause Hormone Therapy: A Q&A With Intira Sriprasert, MD, PhD